This technology utilizes a lovastatin-based compound of Formula 1, commonly used as a hyperlipidemia treatment, or its salt as an active ingredient to restore dermal collagen synthesis impaired by fine dust. It is applicable to cosmetic, food, and pharmaceutical compositions.
Fine dust penetrates pores, causing acne, dryness, and itching, while accelerating skin aging through reduced elasticity and wrinkle formation. However, there has been a lack of proven active ingredients capable of restoring fine-dust-induced skin damage at the dermal level.
This technology repurposes existing statin drugs for dermatological use, inhibiting IL-24 overexpression and promoting collagen synthesis to improve skin elasticity, suppress wrinkles, and strengthen the skin barrier. By utilizing drugs with established safety profiles, it reduces development time and costs for anti-pollution cosmetics, inner beauty products, and skin damage treatments.
This invention was developed with support from the Ministry of Health and Welfare for the discovery and validation of anti-aging and whitening target substances through the investigation of senescence-associated secretory phenotype mechanisms induced by fine dust.
WO2024-123136A1